Latest studies
- RecruitingPHASE2
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
The APEX study is looking at a new medicine called TX000045 for people with high blood pressure in their lungs caused by a certain type of heart failure. It will compare two doses of the medicine against a dummy treatment to see if it helps.
Pulmonary HypertensionHeart Failure With Preserved Ejection FractionArmenia - Recruiting
Clinical Epidemiology in Contemporary Patients With Myelofibrosis.
This study is looking at people living with myelofibrosis, a rare bone marrow condition, across Europe. We're gathering information on how the disease affects them and how it's treated in real life. This helps us understand the condition better and improve care for future patients.
MyelofibrosisArmenia - Active not recruitingPHASE3
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
This study is testing a new tablet, IMU-838, for people aged 18-55 with a type of multiple sclerosis (MS) called relapsing MS. It wants to see how well it works, if it's safe, and if people can tolerate it compared to a dummy tablet.
Multiple Sclerosis, Relapsing-RemittingArmenia - Enrolling by invitationPHASE2
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
This study is for people who are already taking a medicine called ASTX727 for certain blood cancers (like acute myeloid leukaemia, chronic myelomonocytic leukaemia, or myelodysplastic syndromes) in other studies, and it's helping them. It’s a way to keep taking the medicine and gather long-term safety information.
Acute Myeloid LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic SyndromesArmenia - Active not recruitingPHASE3
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
This study looks at a daily tablet called ivosidenib for adults with bile duct cancer that has come back or spread, and has been treated before. It aims to confirm if the treatment is safe and works well, and how it affects quality of life.
CholangiocarcinomaArmenia - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaArmenia - Recruiting
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
This international study is gathering information on a very rare blood cancer called Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). It aims to understand the disease better, look at different treatments, and improve care by collecting data from patients worldwide.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Armenia - RecruitingPHASE3
Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery
This study looks at how well a medication called Atenativ works for people with a rare blood clotting problem (congenital antithrombin deficiency) when they have surgery or deliver a baby. It aims to see if it prevents serious blood clots.
Congenital Antithrombin DeficiencyArmenia - Recruiting
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
This study looks at medical records and tissue samples from people with Nodal Marginal Zone Lymphoma (NMZL) to understand their disease better. Researchers want to find links between gene changes, treatment, and how well people do, hoping to improve future care.
Nodal Marginal Zone LymphomaArmenia